All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Alogliptin Benzoate
Therapeutic Area: Endocrinology Product Name: Nesina
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Teijin Pharma
Deal Size: $1,250.0 million Upfront Cash: Undisclosed
Deal Type: Divestment February 26, 2021
Details:
The portfolio to be divested to Teijin Pharma is comprised of four non-core type 2 diabetes products (Nesina®, Liovel®, Inisync® and Zafatek®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tolvaptan
Therapeutic Area: Endocrinology Product Name: Samsca
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2020
Details:
Oral vasopressin V2-receptor antagonists Samsca® Tablets, Samsca® OD Tablets and SAMSCA® Granules 1% have received regulatory approval in Japan for the indication of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH) in adults.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Alogliptin Benzoate
Therapeutic Area: Endocrinology Product Name: Nesina
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Celltrion
Deal Size: $278.0 million Upfront Cash: $266.0 million
Deal Type: Divestment June 11, 2020
Details:
The portfolio to be divested to Celltrion includes a variety of OTC products and pharmaceutical products such as Nesina® and Edarbi® and Products in a variety of indications.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
